Peter Biotherapeutics

Executive Summary

Peter Biotherapeutics (PeterBio) is a Cambridge, MA-based privately held biotechnology company founded in 2020, dedicated to developing innovative gene and cell therapies for genetic diseases and oncology. The company leverages proprietary gene-editing and gene-repression technologies designed to minimize DNA damage and immunogenicity, addressing key limitations of conventional approaches. With a mission to create safe and effective treatments for as many patients as possible, PeterBio is positioned at the forefront of next-generation genetic medicine. Although the company is still in early stages and has not yet disclosed specific pipeline candidates or clinical trial initiations, its technology platform holds promise for a wide range of indications. The company's focus on reducing off-target effects and immune responses could differentiate its therapies in a competitive landscape. Given its private status and limited public information, PeterBio represents an early-stage opportunity with potential for significant value creation upon achieving key development milestones.

Upcoming Catalysts (preview)

• Q1 2027Lead Program IND Filing70% success
• Q3 2026Preclinical Proof-of-Concept Data Release60% success
• Q4 2026Series A or B Financing Announcement80% success